Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

To effectively use natural rubber (NR) in the rubber industry, it is essential to reduce its viscosity (or molecular weight) through a process known as NR mastication or breakdown, in order to achieve ...

Abstract: Information Extraction (IE) and Text Classification (CLS) serve as the fundamental pillars of NLU, with both disciplines relying on analyzing input sequences to categorize outputs into ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Failed to batch ingest runs: langsmith.utils.LangSmithError: Failed to POST https://api.smith.langchain.com/runs/batch in LangSmith API. maximum recursion depth ...

Tracy J. Wholf is a senior coordinating producer of climate and environmental coverage for CBS News and Stations, based in New York. The Los Angeles wildfires and severe spring thunderstorms are just ...